Franklin Resources Inc. Buys 258,625 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Franklin Resources Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 1,714.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,706 shares of the company’s stock after purchasing an additional 258,625 shares during the quarter. Franklin Resources Inc. owned about 0.48% of Olema Pharmaceuticals worth $1,596,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in OLMA. Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 52.1% in the fourth quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company’s stock valued at $8,839,000 after purchasing an additional 522,799 shares during the period. Schroder Investment Management Group grew its stake in Olema Pharmaceuticals by 548.7% in the 4th quarter. Schroder Investment Management Group now owns 533,111 shares of the company’s stock valued at $2,991,000 after buying an additional 450,924 shares during the last quarter. Pier Capital LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $1,588,000. Pictet Asset Management Holding SA lifted its position in Olema Pharmaceuticals by 12.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company’s stock worth $10,980,000 after acquiring an additional 215,895 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company’s stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Up 7.7 %

Shares of OLMA stock opened at $4.06 on Tuesday. The firm has a 50 day moving average of $4.30 and a 200-day moving average of $7.21. The company has a market cap of $277.43 million, a price-to-earnings ratio of -1.85 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. Analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase & Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Friday, March 28th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.